Scienture HoldingsSCNX -0.33%47 Receivables Turnover is 0.08 as of Mar. 2026. GuruFocus rates SCNX with a GF Score™ of 47/100 and a GF Value™ of $0.35 (Fairly Valued). The stock has 6 warning signs investors should review. Among 656 Healthcare Providers & Services companies, Scienture Holdings ranks worse than 98.32% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Scienture Holdings's Revenue for the
three
months ended in Mar. 2026 was $0.06 Mil. Scienture Holdings's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.73 Mil.
Hence, Scienture Holdings's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.08.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Scienture Holdings Receivables Turnover Related Terms
Scienture Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Scienture Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNX vs WGRX, HEWA, BLMH: Receivables Turnover Comparison
For the Pharmaceutical Retailers subindustry, Scienture Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scienture Holdings Receivables Turnover vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Scienture Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scienture Holdings (SCNX) has a Receivables Turnover of 0.08 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Scienture Holdings and its competitors. According to the industry distribution chart, Scienture Holdings ranks #645 out of 656 companies in the Healthcare Providers & Services industry, placing it in the top 98.3%.
Is Scienture Holdings' Receivables Turnover too high?
Scienture Holdings' current Receivables Turnover is 0.08. The Healthcare Providers & Services industry median Receivables Turnover is 7.69. Scienture Holdings' value of 0.08 is 99% below this industry median. Based on the distribution chart, Scienture Holdings ranks #645 out of 656 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Scienture Holdings has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' Receivables Turnover compare to WGRX and HEWA?
According to the Healthcare Providers & Services industry distribution chart, Scienture Holdings ranks #645 out of 656 companies for Receivables Turnover. This places Scienture Holdings in the lower half of its industry. The industry median Receivables Turnover is 7.69. Scienture Holdings' value of 0.08 is 99% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Healthcare Providers & Services company?
The median Receivables Turnover among Healthcare Providers & Services companies is 7.69, based on 656 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scienture Holdings's current Receivables Turnover of 0.08 is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Scienture Holdings and its competitors. For the Healthcare Providers & Services industry, the median Receivables Turnover is 7.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scienture Holdings's current Receivables Turnover is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Fairly Valued. The stock's GF Value™ is $0.35, compared to a current price of $0.33 — trading 5.3% below its estimated fair value. The current Receivables Turnover is 0.08 and 99% below the Healthcare Providers & Services industry median of 7.69. Scienture Holdings' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current Receivables Turnover is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scienture Holdings (SCNX) Overvalued in 2026?
Based on GuruFocus' analysis, Scienture Holdings stock appears to be undervalued.
The current stock price of $0.33 is trading 5.3% below its estimated GF Value™ of $0.35.
GuruFocus considers Scienture Holdings to be Fairly Valued.
Key valuation signals for SCNX:
Receivables Turnover: 0.08
GF Value™: $0.35 vs. price of $0.33 (5.3% below fair value)
Industry Position: 99% below the Healthcare Providers & Services median (#645 of 656)
No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
47GF Score
Get the complete analysis for SCNX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNX has been successfully added to your 
